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Yondelis
s (trabectedin, ET-743) is a novel marine-derived anticancer compound found in the ascidian Ecteinascidia turbinata.I ti s
currently under phase II/III development in breast cancer, hormone refractory prostate cancer, sarcomas and ovarian cancer. Activity
in breast cancer experimental models has been reported, and preliminary evidence of activity in this setting during the phase I
programme has also been observed. The present study assessed the activity and feasibility of trabectedin in women with advanced
breast cancer previously treated with conventional therapies. Patients with advanced disease previously treated with at least one but
not more than two regimens that included taxanes or anthracyclines as palliative therapy were eligible. Trabectedin 1.5mgm
 2 was
administered as a 24-h continuous infusion every 3 weeks. Patients were kept on therapy until disease progression, unacceptable
toxicity or patient refusal. Twenty-seven patients were included between April 1999 and September 2000. Their median age was 54
years (range: 36–67) and 63% of them had two metastatic sites. Twenty-two patients were performance status 1. All patients had
previously received anthracyclines, and 23 out of 27 patients had received taxanes. Of 21 patients with measurable disease, three
confirmed partial responses, one unconfirmed partial response and two minor responses (49 and 32% tumour shrinkage) were
observed; six patients had stable disease. Median survival was 10 months (95% confidence interval: 4.88–15.18). Transient and
noncumulative transaminitis was observed in most of the patients. The pharmacokinetic profile of trabectedin in this patient’s
population is in line with the overall data available with this schedule. The policy of dose adjustments based on the intercycle peaks of
bilirubin and alkaline phosphatase appears to have a positive impact in the therapeutic index of trabectedin. Trabectedin can induce
response and tumour control in previously treated advanced breast cancer, with manageable toxicity, thus warranting further
development as a single agent or in combination regimens.
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Breast cancer is a chemosensitive disease, and systemic approaches
as neoadjuvant or adjuvant therapy can have a significant impact
on the disease (Crown, 2004; Pegram, 2004). The role of
chemotherapy in the advanced or metastatic setting, however, is
palliative, and novel approaches with taxanes, new vinca
derivatives, new antimetabolites, well-designed combination stra-
tegies and targeted therapies (Hortobagyi, 2003) have been
successfully developed. Nevertheless, long-lasting responses are
rare, and the identification of new drugs that are active in this
setting remains a challenge.
Trabectedin is a marine-derived DNA-interacting agent and
transcription inhibitor (D’Incalci and Jimeno 2003; Martinez et al,
2005) found in the ascidian Ecteinascidia turbinata (Figure 1). It is
currently under phase II/III development in advanced breast,
hormone refractory prostate, pretreated soft tissue sarcoma and
relapsed ovarian cancer. In vitro and in vivo activity have been
reported in experimental breast cancer models, including evidence
of a complete absence of cross-resistance with doxorubicin and
paclitaxel and a positive in vivo therapeutic index in the MX-1
doxorubicin-resistant model (Jimeno et al, 1996). In a phase I
study using a 24-h intravenous (i.v.) continuous infusion (Taamma
et al, 2001), the maximum tolerated dose was 1.8mgm
 2, with
pancytopenia and fatigue as dose-limiting toxicities. At the
recommended dose of 1.5mgm
 2 every 3 weeks, early onset,
reversible and noncumulative transaminitis was observed in the
majority of 25 patients included at this dose level. Twenty per cent
of grade 4 neutropenia was noted in this heavily pretreated
population, and the incidence of thrombocytopenia was low. Drug-
induced emesis could be controlled by conventional supportive
procedures, and there was no alopecia, mucositis, diarrhoea
or other symptomatic toxicities. Results at this recommended
dose level showed no cumulative toxicities. Furthermore, a partial Received 1 February 2006; revised 3 April 2006; accepted 3 April 2006
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sresponse was observed in a previously irradiated area in a taxane-
resistant patient. Based on these promising findings, we conducted
a phase II study of trabectedin in patients with advanced
breast cancer who were resistant or relapsed after conventional
chemotherapy.
PATIENTS AND METHODS
This multicentre, open-label, phase II nonrandomised study
included three French centres. The Ethics Committee of Bice ˆtre
Hospital, France approved the study, and all patients gave their
signed informed consent. The trial was conducted according to the
ICH guidelines and was partially supported by the European
Commission through a BIOMED II demonstration programme
(Contract no. BMH4-CT98-3614 (DG 12-SSMI)).
Patient population
Patients with progressive advanced breast cancer previously
treated with anthracyclines and/or taxanes were eligible for this
study. No more than two previous regimens for metastatic disease
were allowed. Four weeks had to have elapsed between completion
of prior therapy and entry into the study (6 weeks for
nitrosoureas). Normal cardiac, renal and bone marrow functions
were required. Patients with abnormal liver function (serum
bilirubin and alkaline phosphatase oULN; ASAT and
ALATX2.5 ULN) and patients with 450% liver involvement
were not eligible.
Treatment plan and dose modification
Trabectedin 1.5mgm
 2 was administered as a 24-h i.v. continuous
infusion, with appropriate antiemetic medication, every 3 weeks.
Haematological growth factors were not routinely administered.
The dose was reduced to 1.2mgm
 2 in case of grade 4 neutropenia
lasting 45 days, neutropenic fever, or grade 4 thrombocytopenia
and to 1mgm
 2 in case of further bone marrow toxicity.
Treatment was delayed for a maximum of 2 weeks if liver and
bone marrow parameters fell below acceptable levels. No dose
reduction was initially planned for reversible noncumulative
transaminitis. However, in the early stages of a phase II
programme, the incidence of severe multiorgan toxicities leading
to rabdomyolisis and renal failure was of concern, prompting the
investigators to conduct a pharmacokinetic (PK)/pharmaco-
dynamic analysis, the results of which demonstrated the impact of
biliary function at baseline and the clinical relevance of abnormal
intercycle peaks of bilirubin and alkaline posphatase (Go ´mez et al,
2000) as risk factors for serious toxicities. Based on these findings,
the protocol was amended after the first 14 patients had been
entered, and a procedure on dose reduction related to liver toxicity
was included: grade 3–4 transaminitis still present at day 21 but
reversible by day 28 required a dose reduction to 1.2mgm
 2, with
a subsequent dose reduction to 1mgm
 2 permitted if necessary.
An identical dose reduction policy was also mandatory in case of
grade X1 bilirubin or alkaline phosphatase intercycle peaks. In
addition, bilirubin and alkaline phosphatase values had to be
within normal values before the administration of the following
cycle. Treatment was to be continued until disease progression,
unmanageable toxicity or patient refusal.
Response and toxicity assessment
Tumour assessment for all lesions was performed at least every two
cycles. Any evidence of response was confirmed 4 weeks later.
Response was evaluated according to the WHO criteria. A
haemogram was performed at days 8, 15 and 22, and liver
chemistry at days 4, 8, 15 and 22 of each cycle. A biochemical
evaluation, including liver and renal function, was performed
before each treatment cycle.
Pharmacokinetic assessment
On the basis of phase I PK findings (Van Kesteren et al, 2000), a
limited sampling method was proposed. The bioanalysis of
trabectedin in plasma was performed using a miniaturised liquid
chromatography coupled to an electrospray ionisation sample inlet
(turbolon Spray and two mass analysers). Solid-phase extraction
was used to characterise the pretreatment sample. The low limit of
quantitation of the assay is 0.01ngml
 1. Eight millilitres of
peripheral blood were collected at baseline, at 6h after the start of
the infusion, at 30min before the end of the infusion and at 3, 24
and 48h after the completion of the infusion. Plasma concentra-
tion vs time profile was assessed for the set of PK variables defined
in the phase I study (Van Kesteren et al, 2000): area under the
curve, maximum plasma concentration, elimination half-life, total
plasma clearance and volume of distribution at steady state. As
early clinical data indicated a cycle-related tolerance to the
trabectedin-induced hepatobiliary events, the current study
includes, whenever it was feasible, a PK analysis on first and
second cycles.
Statistical analysis
The study design was based on a two-stage Gehan method to
determine response rate, with a standard error o0.10. The
primary end point was tumour response; secondary end points
were safety, duration of response, time to progression and survival.
Duration of response was calculated from the date the response
was recorded to the date of progression. Time to progression and
survival were measured from the first day of study treatment to the
day of progression or death (or last follow-up) and analysed
according to the Kaplan–Meier method.
RESULTS
Patient characteristics
Twenty-seven women with breast cancer from three French
institutions were included. Median age was 54 years (range: 36–
67) and 63% had two metastatic sites. Twenty-three patients (85%)
had previously received anthracyclines or taxanes. Twenty-two
patients were symptomatic at entry. Other patient characteristics
are shown in Table 1.
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Figure 1 Chemical structure of trabectedin.
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sAll 27 patients were treated and considered evaluable for safety.
Twenty-two patients (81.5%) were evaluable for response. Reasons
for nonevaluability were: nonmeasurable lesions (four) and
metastatic lesions from a controlateral breast sarcoma (one). This
latter patient was considered noneligible and excluded from all
efficacy analyses, but the other four patients were included in the
time-to-event analysis (progression and survival). Treatment was
discontinued in one patient owing to toxicity; in another patient,
an unrelated serious adverse event led to patient withdrawal. A
total of 104 cycles were administered. The median number of
cycles per patient was 3 (range: 1–14). Four patients were treated
with six or more cycles of trabectedin.
Response and survival
The overall response rate was 14% (95% confidence interval (CI):
3.5–32%). Three patients attained confirmed partial responses
lasting for 3, 7.3 and 11.3 months, respectively. Drug-induced
tumour shrinkage in the target measurable lesion in these three
patients was 86, 76 and 100%, respectively. A fourth patient
attained an unconfirmed partial response after cycle 2 but
progressed on cycle 4, with no evaluation performed on cycle 3.
Two patients had minor responses (31.8 and 49.4% tumour
shrinkage) that lasted 5 and 6 months, respectively. Six patients
had stable disease. Ten patients had progressive disease, including
three with early progression. The characteristics of patients with
objective response are listed in Table 2. All objective responses
were observed at the second cycle of treatment.
Sixteen patients had an abnormal Ca 15.3 at entry, eight of
whom experienced a median decrease of 43.7% (range 11–92%).
The median time to performance status (PS) deterioration, defined
as PSX2, calculated from the start of trabectedin therapy, was 7.3
months.
Median time to progression was 2.14 months (95% CI: 1.09–3.19
months). Median survival was 10 months (95% CI: 4.88–15.18
months). The projected 1- and 2-year survival rates are 45.5 and
28%. All deaths were due to malignant disease.
Safety
The median actual dose intensity was 443.7mgm
 2week
 1 (range:
304–500), with a median relative dose intensity of 88.7% (range:
60.8–100). After the protocol amendment on liver toxicity was
implemented, median relative dose intensity was 84.4% (range:
60.8–100), compared to 97.7% (range 64.2–100) before the
amendment. Eighteen patients (67%) had at least one cycle
delayed, with a median of one cycle delayed per patient (range:
1–9). A total of 47 cycles were delayed, of which 15 (32%) were due
to non-treatment-related causes. Twenty-seven delays (57%) were
due to haematological reasons and five delays (11%) to other
events. Median duration of delay was 8 days (range: 1–19) for
treatment-related delays and 7 days for delays due to other causes
(range: 1–14). Dose reduction was necessary in eight of the
delayed cycles (17%).
Treatment was discontinued in only one patient owing to
toxicity, grade 4 neutropenia. Toxicity was mainly haematological
(neutropenia) and hepatic (transaminitis) (Table 3). Eighteen
patients suffered fatigue grade 1 or 2 but severe fatigue was noted
in seven patients. The most frequent gastrointestinal toxicities
were nausea and vomiting, usually grade 1 or 2. Mild constipation
occurred in 40% of patients but was mainly due to supportive
medications such as opiates.
Grade 4 neutropenia occurred in one-third of the patients.
Median time to onset of grade 3–4 neutropenia was 13 days after
the infusion. The median duration of grade 4 neutropenia was 6
days. No episodes of neutropenic fever were observed. Almost all
patients experienced an increase of transaminases 4upper normal
limit (UNL), and 75% had elevated alkaline phosphatase.
Transaminitis was transient, reversible and noncumulative, with
an early onset, reaching a peak at a median of 5 days. Whereas 75%
of patients had grade 3–4 ASAT/ALAT increases (45 ULN), all
increases in alkaline phosphatase were grade 1–2 (o5 ULN),
and bilirubin was elevated in only three patients. The median
duration of grade 3–4 cytolysis was 6 and 8 days, respectively, and
Table 1 Patient characteristics
Parameter Number
Median age (range) 54 years (37–67)
ECOG PS at entry
05
12 2
Median number of sites (range) 2 (1–5)
Site of disease
Liver 16
Lung 10
Bone 12
Nodes 11
Breast 6
Skin 5
Pleura 2
Previous therapies
Surgery 27
Radiotherapy 24
Chemotherapy
Median number of previous lines (range) 2 (1–4)
Median number of previous agents (range) 5 (2–7)
Previous exposure
Anthracyclines 27
Taxanes 23
PS¼performance status.
Table 2 Trabectedin: characteristics of patients with objective response
Age PS
Prior CT
lines
a
Prior CT
agents
Anthra clinical
resistance
Tax clinical
resistance Site of disease OR
Number
of cycles
Baseline
CA 15.3
CA 15.3
Maximal nadir TTP
51 0 1+1 5 E E Lung, mediastinal nodes PR 4 26 7 3.0
53 0 2+2 5 E NA Skin, mediastinal nodes PR 12 30 25 11.3
57 1 1+1 4 E E Lung, liver PR 10 1061 125 7.3
46 0 1+2 5 E R Breast, axillary & peritoneal nodes UPR 4 1604 1425 3.5
55 1 1+1 5 E E Liver MR 5 197 88 5.0
53 0 0+3 7 E E Lung, pre-external soft tissue MR 4 32 29 6.0
aAdjuvant+advanced. Anthra¼anthracyclines; CT¼chemotherapy; E¼exposed; MR¼minor response; NA¼information not available; OR¼overall response;
PS¼performance status; R¼primary resistant; Tax¼taxanes; TTP¼time to progression in months; U¼unconfirmed.
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smedian time to recovery to grade 1 (2.5 ULN) was 15 and 16 days
for ASAT and ALAT, respectively. Alkaline phosphatase peaked
later than liver enzymes. The median duration of hyperbilirubi-
naemia was 6 days. All drug-related toxicities were noncumulative,
thus making it possible to administer multiple cycles.
Impact of the protocol amendment in the therapeutic
index of Yondelis
In our study, 14 out of the 27 patients were included after
the protocol amendment. The median number of cycles were
three in both groups of patients. The median dose intensity
(mgm
 2week
 1) was 0.488 and 0.422 before and after the
amendment, respectively. The cohort of patients treated after the
amendment experienced a less frequency of severe neutropenia
(57%) than the ones treated before the amendment (77%).
No patients treated after the amendment had treatment-related
severe fatigue but such clinically important side effect was
observed in four out of 13 cases treated before the implementation
of the dose reduction policy (Fisher’s test; P¼0.04). One
confirmed partial response was reported among the cases treated
before the protocol amendment and two confirmed partial
responses were noted in the cohort included after the implementa-
tion of this dose adjustment policy. The rate of tumour control
(partial plus minor responses plus stable disease) was 38.5% (5/13)
vs 50% (7/14) in those patients who received trabectedin before
and after the amendment, respectively.
Pharmacokinetics
Blood samples were collected and analysed in 10 cases. First- and
second-cycle PKs were assessed in seven patients, whereas in three
patients, PKs were assessed only at the first cycle. Table 4 shows
the PK parameters at the first and second cycles. The results are
fully consistent with PK data from the previous phase I study (Van
Kesteren et al, 2000)
DISCUSSION
The success of alternative chemotherapy in patients with meta-
static breast cancer who have failed after previous therapy
with anthracyclines or taxanes has been modest. Moreover, the
selection of the most beneficial salvage regimen is becoming a
major concern because of the widespread use of these drugs as
first-line chemotherapy. Therefore, the identification of new active
agents feasible for chronic treatment and suitable for combination
therapy is a priority.
The present study has shown that trabectedin is active in
previously treated breast cancer, inducing objective responses and
tumour control. The partial response rate (14%), although modest,
is within the range of what can be expected from an active drug in
this setting and is along the lines of the findings in a recent phase
II study (Gurtler et al, 2005), comparing two dose schedules of
trabectedin in pretreated breast cancer. The authors reported a
13% partial response rate with 1.3mgm
 2 as a 3-h i.v. infusion
every 3 weeks, whereas a weekly lower dose was less active.
Moreover, in the present study, two patients had a confirmed
minor response and six had stable disease. The overall survival
also compares well with other salvage regimens. Evidence of
biological activity, as evidenced by drops in tumour markers, was
observed in eight patients.
Neutropenia and transaminitis were the most commonly
observed drug-related toxicities. Episodes of neutropenia were
transient and no episodes of neutropenic fever occurred. Although
transaminitis occurred in the majority of patients, it never led to
serious adverse events. Other side effects were asthenia and emesis,
which were controllable by corticoids and conventional antiemetic
therapy. The absence of other severe toxicities, including grade 3–
4 alopecia, and the lack of cumulative toxicities make trabectedin
feasible and attractive for long-term palliative use.
In addition to the activity reported for trabectedin as a single
agent, mechanistic (D’Incalci et al, 2002; Kanzaki et al, 2002) and
preclinical (Takahashi et al, 2002; D’Incalci et al, 2003; Meco et al,
2003) studies have noted evidence of in vitro and in vivo synergism
of trabectedin in combination with anthracyclines, taxanes and
platin salts in experimental models of several solid tumours,
including breast cancer. Phase I combination studies have also
reported feasibility and activity in resistant solid tumours when
trabectedin is combined with anthracyclines (Gianni et al, 2003;
Cohen et al, 2005), paclitaxel (Chu et al, 2004), platinum
compounds (Sessa et al, 2004) or capecitabine (Holden et al,
2003). The final results of these phase I studies of trabectedin
combinations will allow us to select the regimen with the best
therapeutic profile for further phase II and potential phase III trials
in previously treated breast cancer. The PK data generated in this
small cohort of patients appears to be consistent with the overall
PK profile of the compound. With the major caveat of the limited
evidence generated, the comparative PKs on first vs second course
suggest similar area under the curve and terminal half-life figures
but a lower Cmax value on the second course of therapy. Ongoing
population PK analysis in large cohorts of cases treated with
trabectedin will provide soon with valuable information on the
PK/pharmacodynamic profile of this compound. In any case, our
results confirm that plasma levels well above the active in vitro
concentrations are reachable and sustainable at dose level that is
feasible for multiple cycles. Such findings, essentially the long
terminal half-life of trabectedin, also support the incorporation of
the 3h i.v. infusion at least in breast cancer, where the rate of
objective response with such short infusion schedule (Gurtler et al,
2005) is identical to the one reported in this study.
A 3-h i.v. infusion has been included in all the trabectedin-
containing combination regimens.
Table 3 Safety profile of trabectedin in advanced pretreated breast
cancer
a
Parameter G1 G2 G3 G4
ASAT 1 6 15 4
ALAT 1 5 12 8
Bilirubin — 2 1 —
Alk-Phos 14 6 — —
Gamma-GT 2 8 12 1
Vomiting 5621
Diarrhea 6 — — —
Mucositis 1 — — —
Fatigue 7 12 3 1
Neutropenia 2499
Thrombotytopenia 2311
Anaemia 7 14 — —
aNCIC-CTC modified criteria/worst grade per patient while on therapy. N¼27.
Table 4 Pharmacokinetic analysis
a
Parameter
Cycle AUC (hlgl
 1) Cmax (pgml
 1) t1/2 CL (l/hm
2) Vss (lm
 2)
First 43.76 1220.4 42.72 66 1010
Second 45.85 997 49.1 67.9 1459.6
amedian values. AUC¼area under the curve; Cmax¼maximum plasma concentra-
tion; CL¼plasma clearance; t1/2¼elimination half-life; Vss¼volume of distribution at
steady state.
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sTrabectedin is a DNA-interacting agent that requires a
functional transcription-coupled nucleotide excision repair (TC-
NER) DNA repair system to induce antiproliferative effects in
experimental cancer models (Takebayashi et al, 2001; D’Incalci
et al, 2003). A retrospective analysis (Van Oosterom et al, 2004)
examining polymorphisms and mRNA expression levels of genes
of the TC-NER and the homologous recombination repair (HRR)
DNA repair pathways in 45 advanced sarcoma patients treated
with trabectedin reported a better outcome in patients bearing a
functional TC-NER pathway. Moreover, low levels of BRCA1,
which is involved in HRR, correlated with a better response rate,
time to progression (P¼0.06) and median survival (P¼0.02).
Human sarcoma primary cultures with mutated p53 have also
shown extreme in vitro sensitivity to trabectedin (A Carnero,
personal communication). These pharmacogenomic findings merit
investigation in breast cancer patients treated with trabectedin. By
elucidating the molecular basis behind individual differences in
outcome, we will be able to design customised models for
therapeutic intervention and maximise the clinical impact of
trabectedin in patients with advanced pretreated breast cancer.
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